Greenwich LifeSciences Expands FLAMINGO-01 Trial to City of Hope

Addition of renowned breast cancer expert Dr. Hope Rugo and City of Hope network sites strengthens clinical trial footprint

Mar. 19, 2026 at 10:35am

Got story updates? Submit your updates here. ›

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, announced the initiation of new clinical sites for its Phase III FLAMINGO-01 trial at City of Hope, one of the largest cancer research and treatment organizations in the U.S. The trial is evaluating the company's immunotherapy GLSI-100 to prevent breast cancer recurrences. Renowned breast cancer expert Dr. Hope Rugo will oversee the trial at City of Hope's network sites in California, Arizona, Georgia, and Illinois.

Why it matters

The addition of City of Hope's extensive network and Dr. Rugo's leadership will strengthen the FLAMINGO-01 trial, which is evaluating a potential new therapy to prevent recurrences in high-risk breast cancer patients. City of Hope's expertise in breast cancer research and clinical trials will be invaluable as Greenwich LifeSciences advances this important study.

The details

The Phase III FLAMINGO-01 trial is designed to evaluate the safety and efficacy of Greenwich LifeSciences' GLSI-100 immunotherapy in HER2 positive breast cancer patients who have completed neoadjuvant and adjuvant trastuzumab-based treatment. The trial now includes clinical sites from City of Hope's network in Los Angeles, Orange County, Arizona, Atlanta, and Illinois, in addition to the existing sites led by Baylor College of Medicine. Dr. Hope Rugo, a world-renowned breast cancer expert, will oversee the trial at the new City of Hope locations and continue to serve on the Steering Committee.

  • The Phase III clinical trial has recently been activated at City of Hope's network sites.
  • Dr. Rugo previously participated in the trial through her site at the University of California San Francisco, where she is Professor Emeritus.

The players

Greenwich LifeSciences, Inc.

A clinical-stage biopharmaceutical company focused on developing an immunotherapy, GLSI-100, to prevent breast cancer recurrences.

City of Hope

One of the largest and most advanced cancer research and treatment organizations in the United States, with a network of sites across multiple states.

Dr. Hope S. Rugo

A world-renowned expert in breast cancer and clinical trial design and execution, who serves as division chief of breast medical oncology and a professor at City of Hope.

Got photos? Submit your photos here. ›

What they’re saying

“I am excited to open this important trial across our City of Hope sites, expanding treatment opportunities for our patients with high-risk early stage HER2 positive breast cancer. It is truly an honor to now represent City of Hope on the Steering Committee. This study aligns with City of Hope's interest in and the importance of harnessing the host immune system to reduce the risk of breast cancer recurrence.”

— Dr. Hope S. Rugo, Division Chief of Breast Medical Oncology and Professor, City of Hope

“We are honored to have Dr. Rugo, a globally recognized leader in breast cancer, now participating in FLAMINGO-01 through her leadership at City of Hope. Her site's expertise and commitment to advancing patient care, which I personally experienced when training these sites, is invaluable as we continue to study GLSI-100. The four City of Hope locations also strengthen our study footprint in some regions of the US where we were not previously covered, providing the study with access to additional population centers.”

— Dr. Jaye Thompson, VP Clinical and Regulatory Affairs, Greenwich LifeSciences

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

The expansion of the FLAMINGO-01 trial to City of Hope's network, led by renowned breast cancer expert Dr. Hope Rugo, strengthens Greenwich LifeSciences' efforts to develop a potential new immunotherapy to prevent breast cancer recurrences in high-risk patients.